BackNovoCure Overview

NovoCure Accounts Payable

NovoCure's accounts payable is $130M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$130.73M
↑ 26.09% YoYΔ $27.05M vs prior year quarter

Peer average

Loading

NovoCure Accounts Payable History

Loading

NovoCure vs. peers: Accounts Payable Comparison

Loading

NovoCure Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

NovoCure (NVCR) FAQ

As of the most recent data (June 2026), NVCR shows a accounts payable of $130M. That compares with $100M in the prior-year period — up 26.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NVCR's accounts payable is now $130M (was $100M) — a 26.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether NovoCure is outperforming or lagging.

Tracking NVCR's accounts payable over time shows whether NovoCure is scaling, shrinking, or reshaping that part of the business. The current reading is $130M That compares with $100M in the prior-year period — up 26.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has NovoCure's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $130M) with ownership activity and broader fundamentals.

NovoCure's accounts payable is $130M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.